Why Influencers Use the FDA to Bash Research Peptides

The FDA approves drugs. That much is true. What most people don't understand is who pays for that approval process, and why that matters enormously when someone uses "FDA approved" as a measure of safety or legitimacy.

Start with the funding structure. The FDA's drug review budget is not primarily funded by taxpayers. It is primarily funded by the pharmaceutical companies whose drugs the FDA reviews. This arrangement has a name, something called PDUFA, the Prescription Drug User Fee Act, which is the law that requires drug companies to pay the FDA directly in exchange for having their applications reviewed. The fee for a single drug application in fiscal year 2024 is $4,198,000. And those fees, paid by the companies being regulated, make up approximately 65% of the FDA's entire human drug review budget.

The companies paying to be regulated are also the companies being regulated. That is not a conspiracy theory. That is the published budget structure.

Now consider what happens when FDA officials leave the agency. A 2018 analysis published in Science tracked medical officers who left the FDA between 2006 and 2019 and found that 62% of them went directly to work for the pharmaceutical industry. The former FDA Commissioner from 2017 to 2019 left his post and joined Pfizer's board of directors the same year. The pharmaceutical industry also spends $374 million per year on federal lobbying, which works out to roughly three lobbyists for every single member of Congress.

This is the system. Money flows in through application fees. Careers flow out through industry jobs. Influence flows in through lobbying. The regulatory body and the regulated industry are not adversarial. They are deeply financially entangled.

So when someone points to FDA approval as the benchmark for whether something is safe or legitimate, they are pointing to this system.

Now here is where research peptides come in, and why they will almost certainly never carry an FDA approval regardless of what the science shows.

Getting a drug approved by the FDA requires navigating that entire fee and review structure, and at the end of the process, the company needs a way to protect its investment. That protection comes through patents. A company spends roughly $985 million in capitalized research and development costs to bring a single new drug to market, according to a 2020 JAMA Internal Medicine analysis, and the only reason that investment makes financial sense is because patent protection allows them to be the exclusive seller for years afterward.

Peptides that occur naturally in the human body cannot be patented in their natural form. The sequence already exists in nature. There is no proprietary claim to own. So no pharmaceutical company will spend close to a billion dollars on the FDA approval process for a compound they cannot then control exclusively in the market. The return on investment simply does not exist.

This is not a legal technicality or a gap in the system. It is the reason FDA approval functions as a commercial filter just as much as a safety filter. Drugs that get approved are drugs that pharmaceutical companies could build a profitable patent-protected business around. Compounds that don't fit that model don't get approved. That tells you something about what the approval label actually measures.

Now contrast that with what compounding pharmacies do. Compounding pharmacies are licensed facilities that can legally prepare custom medications, including some peptides, for patients with a prescription. They operate under FDA oversight in a specific technical sense, meaning they are subject to regulations about sterility and manufacturing standards. But the peptides they compound are not individually FDA approved drugs. They are compounding the same or similar compounds that exist in research chemical markets, just within a licensed facility framework.

When someone argues that compounding pharmacy peptides are safe because of FDA oversight while research chemicals are dangerous because they lack it, they are drawing a distinction that is much thinner than they are implying. The regulatory difference is real but narrow. The underlying compounds are often the same. What differs is the business model wrapped around them.

And that business model matters when you are evaluating someone's motives for making the argument. If a person is selling peptides through a compounding pharmacy while publicly attacking research peptides as unsafe and unregulated, they are using the FDA's credibility to create a competitive advantage for their own product. They are not citing FDA oversight because they care about safety. They are citing it because it differentiates their revenue stream.

You cannot spend years building an audience by positioning yourself as skeptical of pharmaceutical industry influence and then pivot to invoking that same industry's regulatory body as your authority the moment it serves your business. The argument doesn't hold. The FDA is either a captured institution or it isn't. You don't get to use it selectively.

The deeper point here is about understanding what regulatory approval actually signals. It signals that a compound was commercially viable enough for a pharmaceutical company to fund the approval process, and that the company had enough lobbying access and financial staying power to see it through. It does not signal that unapproved compounds are dangerous. It signals that unapproved compounds weren't worth the investment to a patent-protected business.

Those are not the same thing, and conflating them is either a mistake or a sales strategy.

---

References

1. FDA PDUFA Fee Schedule — Federal Register (published annually). FY 2024 application fee: $4,198,000.
2. FDA Budget Justification to Congress — PDUFA user fees fund approximately 65% of CDER/CBER human drug review budget.
3. Piller, C. (2018). "Is FDA's revolving door open too wide?" Science. Found 62% of FDA medical officers who left between 2006-2019 went to work for pharmaceutical industry.
4. OpenSecrets.org — Center for Responsive Politics. Pharmaceutical/health products industry spent $374 million on federal lobbying in 2023, #1 ranked industry. Approximately 1,500-1,800 registered lobbyists (roughly 3:1 ratio to members of Congress).
5. Scott Gottlieb served as FDA Commissioner 2017-2019, joined Pfizer board of directors in 2019.
6. Wouters, O.J., McKee, M., Luyten, J. (2020). "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." JAMA Internal Medicine. Median capitalized cost: $985 million per drug.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness